With a median overall survival rate of one year, metastatic sarcomas pose a substantial threat to patient wellbeing. Although current treatment plans include traditional therapies, such as radiation and chemotherapy, sarcomas’ multiple subtypes require more specific treatment. Third-year resident Jeff Rytlewski, MD, is first author on two articles reviewing the barriers and prospects of sarcoma therapies. […]